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Methods: In protocol 9801, 401 pts with BM from any primary tumor 
were randomized to receive WBRT alone (30 Gy/10 fractions) or MGd, 
5 mg/kg qd x 10 days, with WBRT. The subgroup of 251 pts with 
NSCLC is included in this analysis. In protocol 0211, 554 pts with BM 
from NSCLC were randomized to the same treatments. In both studies, 
eligibility included a KPS ≥ 70, no liver metastases, and ≤ 1 site of 
extracranial metastasis. In both studies, patients underwent a battery of 
neurocognitive tests measuring memory and executive function at base-
line and all subsequent monthly follow-up visits. Progressions were 
deﬁned as a conﬁrmed decline from baseline of 1.5 standard deviations, 
corrected for age and educational background.
Results: 805 pts received WBRT (N=403) or MGd+WBRT (N=402). 
Most pts had multiple BM (81%), extracranial metastases (47%) 
and presented with neurologic deﬁcits (84%). Treatment arms were 
balanced for key prognostic factors. At baseline, 77% of all patients 
had some degree of neurocognitive deﬁcit with 18% having one test 
result abnormal, 20% having two, 18% having three, 16% having four 
and 5% having all ﬁve test results abnormal. Memory was the most 
frequently impaired function (57%). Baseline neurocognitive impair-
ments were balanced across treatment arms. Patients treated with 
MGd+WBRT were less likely during follow-up to show evidence of 
neurocognitive progression in memory function (HR=0.80, p=0.047), 
in executive function (HR=0.74, p=0.028) or in a combined score for 
all tests, (HR=0.78, p=0.02).
Conclusions: Consistent with the delay in time to clinical neuro-
logic progression seen in a previous pooled analysis, treatment with 
MGd+WBRT decreased progression in each function measured by 
standardized neurocognitive testing in the pooled dataset from 2 ran-
domized phase III trials.
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Background: In early stage NSCLC, neoadjuvant chemotherapy is a 
promising option, although conclusive evidence is yet to be supplied. 
The NATCH trial was designed in order to address whether neoadjuvant 
or adjuvant paclitaxel(P)/carboplatin(C)improves disease-free survival 
compared to surgery alone in early-stage NSCLC. Analyses of toxicity, 
response rate, resectability rate and surgical mortality rates have now 
been carried out on patients randomized to the neoadjuvant arm.
Methods: Clinical stage I (> 2 cm), II, T3N1 NSCLC consenting 
patients are randomized to surgery alone or 3 cycles of neoadjuvant PC 
(P:200 mg/m2/ C AUC:6 on day 1 every 3wk), or surgery followed by 3 
cycles of adjuvant PC at the same schedule. This prospective, random-
ized trial planned to include 624 patients.
Results: Between April 2000 and March 2007, 623 patients have been 
accrued, 201 on the neoadjuvant arm; 211 on the adjuvant arm and 
211 on the surgery arm. On the neoadjuvant arm, demographic data is 
now available for 162 patients: 89% male; median age 64 years (range, 
37-78); 45% PS 0; 53% squamous cell, 27% adenocarcinoma, 13% 
large cell; 7% stage IA, 64% IB, 2% IIA, 24% IIB, 2.5% T3N1. To 
date, neoadjuvant chemotherapy has been well tolerated. No unex-
pected toxicities have been seen with 12% of patients having grade 3-4 
neutropenia and 43% grade 1-2 anemia. Major radiographic response 
has been observed in 59% of patients and progression during chemo-
therapy occurred in 6%. No patient characteristics were predictive for 
clinical response. At thoracotomy resection procedures were: lobec-
tomy or bilobectomy in 70%; pneumonectomy in 26%; and explorative 
thoracotomy due to unresectable disease in 3% of patients. Thirty-day 
post-operative mortality was 4%. At surgery, 9% patients had patho-
logic complete response; 75% N0-1 disease (with persistent T tumor), 
and 15% had pathologic N2 disease. 
Conclusion: Our ﬁndings suggest that neoadjuvant chemotherapy 
in early NSCLC is feasible with manageable toxicity and with good 
resectability rates. Mature survival results of the NATCH trial are 
expected in 2009.
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Background: Surgery offers the best chance of cure for patients with 
NSCLC, but the 5-year survival rate is modest, and improvements are 
urgently required. Following striking results in favour of neo-adjuvant 
chemotherapy in 2 small trials, the current trial was designed to investi-
gate whether, in patients with operable NSCLC of any stage, platinum-
based chemotherapy given prior to surgery would improve outcomes.
Methods: The primary endpoint was overall survival, and secondary 
endpoints were: quality of life, pathological staging, resectability rates, 
extent of surgery, and time to and site of relapse. The trial was designed 
to detect a 15% improvement in 3-year survival (from 40% to 55%) with 
neo-adjuvant chemotherapy (5% signiﬁcance level, 90% power), which 
required 450 patients and 233 events (deaths). Patients were randomised 
to receive either surgery alone (S), or 3 cycles of platinum-based che-
motherapy prior to surgery (CT-S), clinicians choosing (pre-randomisa-
tion) the chemotherapy from 6 standard regimens. Quality of Life was 
assessed by patients completing the SF-36 questionnaire at baseline 
(pre-randomisation), 6 and 12 months, and then annually to 5 years. 
